Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
22 janv. 2025 09h00 HE
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...
Hepion Pharmaceuticals Announces $9.0 Million Public Offering
22 janv. 2025 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Bioxytran Announces Government Interest After Initial BARDA Techwatch Light Meeting
07 janv. 2025 09h00 HE
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 07, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
11 déc. 2024 08h00 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a...
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
04 déc. 2024 16h56 HE
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
02 déc. 2024 19h00 HE
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a...
GT Biopharma Reports Third Quarter 2024 Financial Results
14 nov. 2024 16h00 HE
|
GT Biopharma, Inc.
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in...
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
13 nov. 2024 07h00 HE
|
BioRestorative Therapies, Inc
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
05 nov. 2024 07h10 HE
|
BioRestorative Therapies, Inc
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative...
Interim results for the six months ended June 30, 2024
26 sept. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an...